학술논문
Persistence of IgG4 as a potential serological marker of disease activity in patients with epidermolysis bullosa acquisita treated with rituximab.
Document Type
Article
Author
Source
Subject
*EPIDERMOLYSIS bullosa
*RITUXIMAB
*DISEASE remission
*RESEARCH personnel
*
*
*
Language
ISSN
0926-9959
Abstract
This article discusses a study conducted in Brazil on patients with epidermolysis bullosa acquisita (EBA), a rare autoimmune blistering disease. The study focused on the use of rituximab (RTX) as a treatment option for EBA. The researchers evaluated the clinical features and the IgG subclass profile in EBA patients treated with RTX. They found that the persistence of circulating IgG4 after RTX treatment was associated with partial remission of the disease. This preliminary finding suggests that IgG4 antibodies may serve as a marker of disease activity in EBA after RTX treatment. Further research with a larger cohort of patients is needed to better understand the potential use of IgG subclasses as a follow-up marker for EBA activity in patients on RTX. [Extracted from the article]